Live Action News
October 14, 2025
By Carole Novielli
Posted by Morgana
—
**The Mystery Behind Generic Abortion Pill Maker Evita Solutions, LLC**
The mystery surrounding the generic abortion pill manufacturer Evita Solutions, LLC is reminiscent of the secrecy that once enveloped the original abortion pill maker approved in 2000, Danco Laboratories. Like Danco, little is known about Evita Solutions, and no official spokespersons from the company have been identified to date.
—
### Key Takeaways:
– Manufacturers of the generic abortion pill have historically been shrouded in secrecy.
– Last month, under former President Trump’s FDA, a new generic version of the drug mifepristone from Evita Solutions, LLC was approved.
– Little is known about Evita Solutions aside from the fact that the company is based in Virginia and its principal is Robert Patane.
– Evita Solutions’ only known product is the generic abortion pill.
—
### The Backstory
Mifepristone, commonly known as the abortion pill, was first approved in 2000. Since then, several regulatory changes have taken place under FDA oversight. According to Clinton’s FDA, the drug was initially approved to be taken more than 24 hours before misoprostol.
However, similar to Danco Laboratories, Evita Solutions remains largely secretive. Aside from identifying Robert Patane as the principal, no other executives or spokespersons have been publicly revealed. Live Action News has identified a “Bob” Patane, who was the President of Pharmacist Pharmaceutical, LLC, but no confirmed connection between Patane, J&P, or other related entities has been established.
—
### What’s Ahead?
U.S. Senator Josh Hawley of Missouri has formally requested an explanation from the FDA regarding its recent approval of the new generic mifepristone drug. In a letter to FDA Commissioner Dr. Robert Califf (note: the original text erroneously names Marty Makary), Hawley expressed alarm at the decision, stating it seemed to disregard scientific data in favor of advancing an ideological agenda.
KTTN.com reported that the senator asked the FDA to respond by October 10, 2025, and posed several detailed questions concerning the approval process, including:
– Whether Commissioner Califf personally participated in the approval of the ANDA 216616 application and the nature of that involvement.
– A detailed timeline of the submission and approval process for ANDA 216616.
– Explanation of the FDA’s evaluation of therapeutic equivalence for the generic drug and whether potential risks of increased adverse events were considered.
– Clarification on how recent safety data about mifepristone influenced the approval decision.
– Whether the FDA considered Evita Solutions LLC’s stated goals and mission during approval.
– Whether the generic will remain on the market without adhering to any future safety standards emerging from ongoing reviews or updated Mifepristone Risk Evaluation and Mitigation Strategy (REMS).
—
### Ongoing Legal Challenges to Abortion Pill Expansion
A continuing lawsuit challenges the FDA’s expansion of abortion pill distribution. Initially filed as *Alliance for Hippocratic Medicine v. FDA* in Amarillo, Texas, by a group of doctors, the U.S. Supreme Court ruled in 2024 that the doctors lacked standing to sue. Subsequently, in January 2025, U.S. District Judge Matthew Kacsmaryk allowed the states of Missouri, Kansas, and Idaho to intervene and file complaints.
In May 2025, the Department of Justice under the Trump administration called for dismissal of the lawsuit. In August, Texas and Florida petitioned to intervene, and more recently, Louisiana along with Rosalie Markezich — a Louisiana resident claiming to be adversely affected by FDA’s decision to allow abortion pills by mail — have moved to intervene as well.
The venue for the case was recently moved out of Texas to Missouri. Judge Kacsmaryk was originally assigned to hear the case in Texas.
—
### Consider This
Live Action News has previously documented the secrecy surrounding the original 2000 approval of mifepristone, including the hiding of the identities of experts involved in the approval process. The full FDA records have yet to be fully disclosed, fueling ongoing questions about potential financial or other conflicts of interest among past and present FDA reviewers and experts that might have influenced approval and expansion decisions.
A February 2025 FDA update revealed that since 2000, approximately 7.5 million women have used mifepristone in the U.S. for medical termination of pregnancy through the end of December 2024.
The FDA stated that “adverse events cannot with certainty be causally attributed to mifepristone” but reported receiving “serious adverse events” in patients who took the drug. According to the FDA website, as of December 31, 2024, there have been 36 reports of deaths in patients associated with mifepristone since its approval in September 2000.
—
### Topics:
Health / Medicine
### Keywords:
abortion, abortion pill, chemical abortion, Evita Solutions, medical abortion, mifepristone, misoprostol, pro-life
—
**Support Our Work**
Click here to donate by Credit Card
Or click here to donate by PayPal
Or mail donations to:
Free Republic, LLC
PO Box 9771
Fresno, CA 93794
Thank you very much and God bless you.
—
*Disclaimer:* Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the views of Free Republic or its management. All materials posted herein are protected by copyright.
https://freerepublic.com/focus/f-chat/4346713/posts